NCT02380287View on ClinicalTrials.gov

First-in-human Study to Evaluate Safety, Tolerability and Pharmacokinetics of Various Doses of BCD-085 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

September 30, 2015

Study Completion Date

October 31, 2015

Conditions
Healthy
Interventions
DRUG

humanized monoclonal antibody against human IL-17

Sponsors

Lead Sponsor

Biocad
All Listed Sponsors
lead

Biocad

INDUSTRY